Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Q3 2025 Earnings Presentation
10 slides from Orasure Technologies's earnings presentation, Nov 5, 2025
Slide 1: OraSure Q3 2025 Investor Update
OraSure Q3 2025 Investor Update NOVEMBER 2025 Exhibit 99.2
Slide 2: Disclaimers: Forward-Looking Statements
© 2025 OraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the “Company” or “OraSure”) contains certain “forward-looking statements” within the meaning of federal securities laws, including with respect to products, pro
Slide 3: Disciplined execution driving stronger platform for growth
© 2025 OraSure Technologies, Inc. 3OTI Proprietary Disciplined execution driving stronger platform for growth Three years of progress in transformation strategy Strengthen our Foundation Elevate our Core Growth Accelerate our Profitable Growth Cost productivity • One OTI: combined 2 business units i
Slide 4: Financial performance summary
© 2025 OraSure Technologies, Inc. 4OTI Proprietary Financial performance summary Innovating and operating with disciplined execution and accountability Q3 results • Total Revenue: $27.1 million • Core Revenue: $27.0 million • Non-GAAP Gross Margin: 44.2% External environment: OTI is diversifying its
Slide 5: Strategy to accelerate growth with near-term catalysts in attractive markets
© 2025 OraSure Technologies, Inc. 5OTI Proprietary Strategy to accelerate growth with near-term catalysts in attractive markets … Executing on Near-Term Innovation Delivering differentiated product pipeline with near-term milestones … aligned with long-term healthcare trends Expanding Product Pipeli
Slide 6: Product roadmap: anticipated near-term milestones
© 2025 OraSure Technologies, Inc. 6OTI Proprietary Product roadmap: anticipated near-term milestones Description Protein-specific blood collection & sample stabilization At-home first-void urine self-collection Disposable molecular dx, rapid test Blood self-collection; Dot = dried blood spot vs. cap
Slide 7: Expanding our pipeline in high-value growth markets
© 2025 OraSure Technologies, Inc. 7OTI Proprietary Expanding our pipeline in high-value growth markets Illustrative examples leveraging OTI strengths Notes: •Example criteria are not all inclusive •Matrix excludes less attractive opportunities Example criteria: Market size Growth rate Profitability
Slide 8: OraSure today: stronger, focused, and executing for sustainable growth
© 2025 OraSure Technologies, Inc. 8OTI Proprietary OraSure today: stronger, focused, and executing for sustainable growth Strengthen our Foundation Elevate our Core Growth Accelerate our Profitable Growth
Slide 9: Appendix
© 2025 OraSure Technologies, Inc. 9 Appendix
Slide 10: Reconciliation of Non-GAAP Gross Margin
© 2025 OraSure Technologies, Inc. 10 Reconciliation of Non-GAAP Gross Margin OraSure Technologies GAAP to Non-GAAP Reconciliation ($ in 000's)